Seaport Therapeutics

Executive Summary

Seaport Therapeutics is a Boston-based private biopharmaceutical company focused on developing novel neuropsychiatric medicines. Founded in 2023 and spun out of PureTech Health, the company applies innovative chemistry to known biological mechanisms to create new chemical entities (NCEs) with improved pharmacokinetic profiles. This approach aims to enhance efficacy and tolerability in treating conditions such as depression, anxiety, and addiction. The company has raised $100 million to advance its pipeline of CNS-targeted therapies. Seaport's lead program, SPT-101, is a prodrug of a validated neurotransmitter modulator designed for improved delivery and reduced side effects. The candidate is currently in Phase 2 trials for major depressive disorder, with topline data expected later this year. Additionally, the company is advancing a second asset, SPT-102, targeting generalized anxiety disorder, which is poised to enter Phase 2. With a strong scientific foundation and a focus on addressing high unmet needs in neuropsychiatry, Seaport Therapeutics represents a promising player in the CNS space, though it remains early-stage with clinical execution risk.

Upcoming Catalysts (preview)

• Q4 2026Topline data from Phase 2 trial of SPT-101 in major depressive disorder60% success
• Q2 2026Initiation of Phase 2 trial for SPT-102 in generalized anxiety disorder70% success
• Q3 2026FDA feedback on Phase 3 program design for lead candidate80% success